Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 369-383

  Bucerius, Jan ^a,b,c,d   Mani, Venkatesh ^a,e   Moncrieff, Colin ^a   Machac, Josef ^a   Fuster, Valentin ^e,f   Farkouh, Michael E ^a,e   Tawakol, Ahmed ^g   Rudd, James H F ^h   Fayad, Zahi A ^a,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Marie Josee and Henry R Kravis Center for Cardiovascular Health   (United States)

^f CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^g HARVARD UNIVERSITY   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

FDG circulation time; FDG dose; FDG Pet; Prescan glucose; Vessel wall inflammation

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AORTA; ARTICLE; CAROTID ARTERY; CIRCULATION TIME; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; EMBRYO; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JUGULAR VEIN; MAJOR CLINICAL STUDY; MALE; PET-CT SCANNER; PROSPECTIVE STUDY; SUPERIOR CAVA VEIN; VASCULITIS; ADULT; AGED; CARDIOVASCULAR DISEASE; CAVA VEIN; COMPUTER ASSISTED TOMOGRAPHY; DIET RESTRICTION; INFLAMMATION; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; AGED; AORTA; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; FASTING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; VENAE CAVAE;

EID: 84897089999     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2569-6     Document Type: Article

References (32)

1. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11.
2. Rudd JHF, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1009-16.
3. Elkhawad M, Rudd JHF. Radiotracer imaging of atherosclerotic plaque biology. Cardiol Clin. 2009;27:345-54.
4. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24.
5. Sheikinea Y, Akramc K. FDG-PET imaging of atherosclerosis: do we knowwhatwe see? Atherosclerosis. 2010;211:371-80.
6. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J. 2012;33:1309-17.
7. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, et al. Vascular inflammation imaging with 18F-FDG PET/CT: when to image? JNucl Med. 2009;50:854-7.
8. Rudd JH, Machac J, Fayad ZA. Simvastatin and plaque inflammation. J Am Coll Cardiol. 2007;49:1991; Author reply 1991-2.
9. Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis. 2007;192:453-4; Author reply 451-2.
10. Davies JR Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F-fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642-7.
11. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31.
12. Rudd JHF, Elkhawad M, Fayad ZA. Vascular imaging with 18F-FDG PET/CT: optimal 18F-FDG circulation time? J Nucl Med. 2009;50:1560.
13. Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. JNucl Med. 2010;51:1015-20.
14. Zhuang HM, Cortés-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martínez-Lázaro R, et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun. 2001;22:1123-8.
15. Lee WW, Chung JH, Jang SJ, Eo JS, Park SY, Sung SW, et al. Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. J Surg Oncol. 2006;94:607-13.
16. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-7.
17. Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med. 2009;50:178-83.
18. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
19. Bucerius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, et al. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging. 2011;4:1195-205.
20. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6.
21. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871-8.
22. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12:294-301.
23. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19:708-23.
24. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T; dal-PLAQUE Investigators, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378: 1547-59.
25. Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza JM, et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J. 2011;162:214-21.
26. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20.
27. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248-57.
28. Deichen JT, Prante O, Gack M, Schmiedehause K, Kuwert T. Uptake of [(18)F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging. 2003;30: 267-73.
29. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730-5.
30. Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23:545-50.
31. Bucerius J, Mani V, Moncrieff C, Rudd JH, Machac J, Fuster V, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall (18)f-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol. 2012;59:2080-8.
32. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207:139-43.